Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Pharmasyntez commences production of gensulins in Russia
- By Newsdesk
- Russia
- Jul 04, 2023
PharmaSyntez, a leading technology enterprise in Russia specializing in state-of-the-art pharmaceuticals, is nearing the launch of a revolutionary trio of recombinant human insulin products: Gensulin M30, Gensulin H, and Gensulin P. These advanced medical compounds will be manufactured at the state-of-the-art Pharmasyntez-Nord plant, which has the capacity to produce over 5 million units of insulin annually. The products will be available in various presentations, including vials, disposable syringe pens, and cartridges for reusable syringe pens.
In the upcoming fall, PharmaSyntez will initiate the production of insulin analogs such as insulin glargine and insulin lispro. These groundbreaking products are the result of a collaboration between PharmaSyntez and Gan & Lee Pharmaceuticals from China. This collaboration aims to address the crucial objective of providing Russian patients with high-quality domestic alternatives to essential medications.
Pharmasyntez-Nord, a division of the Pharmasyntez corporate group, is dedicated to the development of cutting-edge and highly effective medications for the treatment of cancer, autoimmune disorders, and endocrine system disorders. They achieve this through their advanced research and manufacturing facility.
Currently, Pharmasyntez-Nord produces an impressive range of 45 different oncology medications, with an exceptional 99% of them being classified as vital and essential drugs by the Russian Ministry of Health.